{"id":"NCT00486031","sponsor":"Bausch Health Americas, Inc.","briefTitle":"Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study","officialTitle":"A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-10","primaryCompletion":"2008-04","completion":"2008-12","firstPosted":"2007-06-13","resultsPosted":"2018-01-19","lastUpdate":"2019-08-15"},"enrollment":443,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Inflammatory Bowel Disease","Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"Balsalazide Disodium","otherNames":[]}],"arms":[{"label":"balsalazide disodium tablets,3.3 g BID,","type":"OTHER"}],"summary":"The objective of the study is to evaluate the long-term safety and tolerability of treatment with balsalazide disodium tablets in subjects who are in remission from ulcerative colitis or who have mildly to moderately active UC.","primaryOutcome":{"measure":"Incidence of Treatment Emergent AEs","timeFrame":"24 Months","effectByArm":[{"arm":"Balsalazide Disodium","deltaMin":273,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":95,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":440},"commonTop":["Worsening UC","Diarrhea","Abdominal pain","Headache","Urinary tract infection"]}}